Mar. 31, 2023
sparsentan
FIC oral, once-daily, dual ETA/AT1 antagonist FDA-approved for proteinuria reduction in primary IgAN opt. of known ETA/AT1 antagonist FDA accelerated approval, February 17, 2023 Travere Therapeutics, San Diego, CA
FIC oral, once-daily, dual ETA/AT1 antagonist FDA-approved for proteinuria reduction in primary IgAN opt. of known ETA/AT1 antagonist FDA accelerated approval, February 17, 2023 Travere Therapeutics, San Diego, CA